SecBot SecBot
8-K ·Filed May 13, 2026

TARA

Protara Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001213900-26-055462
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor upcoming data presentations at AUA (May 15) and ISSVA (May 20) for clinical catalysts, and the BLA submission timeline for LMs. The stock is likely to trade on pipeline progress rather than quarterly financials.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Protara Therapeutics reported Q1 2026 net loss of $17.8M ($0.31/sh), beating the $-0.36 consensus by ~14%. Cash stood at $177M, sufficient into 2028. The company intends to submit a BLA for TARA-002 in lymphatic malformations in 2H 2027 and expects to complete ADVANCED-2 enrollment in 2H 2026. The earnings beat is positive, but widening losses and the lack of revenue limit the impact.

Key Financial Metrics

EPS
−$0.31
est −$0.36 · +13.9%
Rating
beat

Key Facts

  • Net loss Q1 2026: $17.8M vs $11.9M in Q1 2025
  • EPS: -$0.31 vs consensus -$0.36 (13.9% beat)
  • Cash and investments: $177.4M as of March 31, 2026
  • BLA submission for TARA-002 in LMs targeted for 2H 2027
  • ADVANCED-2 trial enrollment completion expected in 2H 2026
  • R&D expenses increased to $13.6M from $9.1M YoY

Financial Impact

EPS beat of ~14% but net loss widened by 49% YoY; no revenue stream

epscash and cash equivalentsnet loss

Risk Factors

  • Clinical trial delays or negative data
  • Cash burn rate increasing with trial expansion
  • Dilution risk from potential future equity offerings

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-055462
Document: ea0288581-8k_protara.htm0001213900-26-055462
Document: 0001213900-26-055462-index-headers.html0001213900-26-055462
Document: 0001213900-26-055462-index.html0001213900-26-055462
Document: 0001213900-26-055462.txt0001213900-26-055462
8-K Data (Synthetic)0001213900-26-055462

Track record

13 reports on TARA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 Viewing No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026